Submission of Matters to a Vote of Security Holders.
OnMay 31, 2023 ,Context Therapeutics Inc. ("the Company") held its 2023 Annual Meeting of Stockholders (the "Annual Meeting"). As ofApril 3, 2023 , the record date for the Annual Meeting, there were 15,966,053 shares of Company common stock issued and outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 10,169,489, or approximately 63.69%, were present or represented by proxy, which constituted a quorum. The holders of shares of Company common stock are entitled to one vote for each share held. Set forth below are the final voting results for the proposals submitted to a vote of the Company's stockholders at the Annual Meeting, which were described in the Company's definitive proxy statement filed with theSecurities and Exchange Commission onApril 6, 2023 . No other matters were considered or voted upon at the meeting.
Proposal 1. To ratify the selection by the Audit Committee of the Board of
Directors of
The Company's stockholders ratified the appointment of
For Against Abstentions Broker Non-Votes Ratification of 9,827,096 232,432 109,961 ---CohnReznick LLP
Proposal 2. To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of its outstanding common stock at a reverse stock split ratio ranging from any whole number between 1-for-2 and 1-for-50, subject to and as determined by the Board of Directors.
While proposal 2 received the affirmative vote of a majority of the shares present or represented by proxy at the Annual Meeting, the proposal was not approved because stockholders holding a majority of the outstanding shares of Company common stock entitled to vote did not vote "FOR" the proposal. The voting on this proposal is set forth below:
For Against Abstentions Broker Non-Votes Amendment to the Company's 7,809,550 2,326,090 33,849 --- Amended and Restated Certificate of Incorporation to effect a reverse stock split
--------------------------------------------------------------------------------
© Edgar Online, source